Biotech firm Tempest faced challenges in securing additional funding due to a market downturn. Despite a history of mergers and setbacks, their promising asset, amezalpat, showed positive results in a Phase 2 trial for hepatocellular carcinoma treatment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing